Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization

Cornea

Volumn 30, Issue 10, 2011, Pages 1110-1114

  Yeung, Sonia N ^a   Lichtinger, Alejandro ^a   Kim, Peter ^a   Amiran, Maoz D ^a   Slomovic, Allan R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

bevacizumab; corneal; neovascularization; subconjunctival

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; CORNEA; CORNEAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; YOUNG ADULT;

EID: 80052776540     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31821379aa     Document Type: Article

References (39)

1. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257. (Pubitemid 18005952)
2. Loeffler KU, Seifert P. Unusual idiopathic lipid keratopathy: a newly recognized entity? Arch Ophthalmol. 2005;123:1435-1438. (Pubitemid 41429748)
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
4. Coster DJ. Factors affecting the outcome of corneal transplantation. Ann R Coll Surg Engl. 1981;63:91-97. (Pubitemid 11167469)
5. Khodadoust AA. The allograft rejection reaction: the leading cause of late failure of clinical corneal grafts. In: Porter R, Knight J, eds. Corneal Graft Failure (Ciba Foundation Symposium). Amsterdam, The Netherlands: Elsevier; 1973:151-164.
6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487. (Pubitemid 24356306)
7. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22. (Pubitemid 28040457)
8. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000;70:419-428. (Pubitemid 30658885)
9. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378. (Pubitemid 16105166)
10. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335. (Pubitemid 40848295)
11. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:363e5-372e5.
12. Bashshur ZF, Bazarbachi A, Schakal A, et al. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;142:1-9. (Pubitemid 43946791)
13. Figueroa MS, Contreras I, Noval S, et al. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol. 2010;94: 1052-1056.
14. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695:e1-e15.
15. Yeung SN, Paton KE, Waite C, et al. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma. Can J Ophthalmol. 2010;45:269-273.
16. Hasanreisoglu M, Weinberger D, Mimouni K, et al. Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol. 2009;19:607-612.
17. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
18. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147. (Pubitemid 351158729)
19. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982. (Pubitemid 47329805)
20. Oh JY, Kim MK, Wee WR. Subconjunctival and intracorneal bevacizumab injection for corneal neovascularization in lipid keratopathy. Cornea. 2009; 28:1070-1073.
21. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989;30:1588-1593. (Pubitemid 19185963)
22. Joussen AM, Kruse FE, Völcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999;237:920-927. (Pubitemid 29484167)
23. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110: 405-407.
24. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085. (Pubitemid 24139577)
25. Qian CX, Bahar I, Levinger E, et al. Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:1090-1092.
26. Gerten G. Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea. 2008;27:1195-1199.
27. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249. (Pubitemid 32751680)
28. Azar DT. Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:264-302. (Pubitemid 46495064)
29. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522. (Pubitemid 30624378)
30. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci. 2004;45: 2666-2673. (Pubitemid 38998863)
31. Bachmann BO, Luetjen-Drecoll E, Bock F, et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol. 2009;93:1075-1080.
32. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
33. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007;48:2545-2552. (Pubitemid 351261204)
34. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2007;245: 1577-1579. (Pubitemid 47423342)
35. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008;27:992-995.
36. Vassileva PI, Hergeldzhieva TG. Avastin use in high risk corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 2009;247:1701-1706.
37. Foroutan A, Fariba B, Pejman B, et al. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty. Cornea. 2010;29:1268-1272.
38. Cursiefen C, Rummelt C, Küchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19:526-533. (Pubitemid 30460894)
39. Lin CT, Hu FR, Kuo KT, et al. Early but not late treatment with bevacizumab (Avastin) can inhibit corneal neovascularization and conjunctivalization in rabbit limbal insufficiency. Invest Ophthalmol Vis Sci. 2010;51:6277-6285.